intrommune_icon_500x500.png
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
October 26, 2022 09:35 ET | Intrommune Therapeutics
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose...
intrommune_icon_500x500.png
Intrommune Expands and Strengthens Senior Leadership Team
September 28, 2022 09:35 ET | Intrommune Therapeutics
Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development Appointment of William Berger, MD, MBA as Head of...
intrommune_icon_500x500.png
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
June 22, 2022 09:31 ET | Intrommune Therapeutics
Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...
intrommune_icon_500x500.png
Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory
June 01, 2022 13:33 ET | Intrommune Therapeutics
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
intrommune_icon_500x500.png
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
April 06, 2022 08:30 ET | Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
intrommune_icon_500x500.png
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
February 08, 2022 08:30 ET | Intrommune Therapeutics
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing in Fully Enrolled Cohort 2 Intrommune Launches Series B Financing NEW YORK, Feb. 08, 2022 (GLOBE...
intrommune_icon_500x500.png
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
December 21, 2021 09:39 ET | Intrommune Therapeutics
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Participates in the Forsyth dentech 2021 Conference
September 22, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
intrommune_icon_500x500.png
Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board
September 21, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
intrommune_icon_500x500.png
Intrommune Therapeutics Announces Arrival of Stuart Loesch as New CCO
September 08, 2021 10:02 ET | Intrommune Therapeutics
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...